Furthermore, knocking down STAT3 in mutant KRAS colorectal cancer cells, but not wild‐type KRAS cells resulted in enhancement of cells’ response to oxaliplatin and 5‐FU.87 This evidence concerns the gene KRAS and colorectal cancer.